A vaccine targeting a protein to treat pancreatic cancer
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
This study is testing a new vaccine designed to help people with pancreatic cancer by boosting their immune system to fight the disease more effectively.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leukogene Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Charleston, UNITED STATES) |
| Project ID | NIH-10897104 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine aimed at treating pancreatic ductal adenocarcinoma (PDAC), one of the most lethal forms of cancer. The approach involves targeting the AGR2 protein, which is highly expressed in over 90% of PDAC patients, using a conjugate of this protein with a bacterial superantigen to stimulate a strong immune response. The study will test the effectiveness of this vaccine in generating an anti-cancer immune response, potentially improving treatment outcomes for patients with PDAC. The research is based on preliminary findings that suggest this method could enhance the body's ability to fight this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new effective treatment option for patients suffering from pancreatic cancer.
How similar studies have performed: While immunotherapy has shown promise in treating other cancers, this specific approach targeting AGR2 in PDAC is novel and has not been extensively tested in clinical settings.
Where this research is happening
Charleston, UNITED STATES
- Leukogene Therapeutics, INC. — Charleston, United States (Active)
Researchers
- Principal investigator: Robinson, Reeder Mcneil — Leukogene Therapeutics, INC.
- Study coordinator: Robinson, Reeder Mcneil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.